Foshan Ampze Biopharma

Foshan Anpuze Biopharma (also known as Annpobio) is a Chinese biotechnology company founded in 2010, specializing in the development and industrialization of monoclonal antibody (mAb) therapeutics. Headquartered in Foshan, Guangdong, the company was established by a team of experts with extensive experience in the U.S. biopharmaceutical industry. Ampze operates a robust technology platform for high-expression cell line development, process optimization, and large-scale GMP manufacturing. Its lead candidate, APZ001, is a biosimilar of Cetuximab (Erbitux) that has completed Phase 3 clinical trials for metastatic colorectal cancer. In addition to its internal drug pipeline, the company provides CRO and CDMO services to support the development of biologics for global partners.